Carregant...
Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...
Guardat en:
| Publicat a: | ACS Omega |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Chemical Society
2020
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758955/ https://ncbi.nlm.nih.gov/pubmed/33376898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c04942 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|